Article Rich General Call for prevention of Cross-Contamination to drive the Single-use Bioprocessing Market

Call for prevention of Cross-Contamination to drive the Single-use Bioprocessing Market

PersistenceMarketResearch states that the global single-use bioprocessing market will witness a CAGR of more than 17% between 2020 and 2030.

Single-use technologies are proving to be scalable and strong – right from scale-up/lab to cGMP production applications inclusive of bioprocessing equipment, automation, rigid containment product, and flexible containment product portfolio.

The key participants are getting benefited with plug-and-play nature on the part of single-use bioprocessing equipment backed by inclination towards usage of high-end polymer materials. Also, there are negligible chances of cross-contamination with less floor space being used.

North America holds the largest market share. This could be credited to large-scale biopharmaceutical manufacturing facilities being present in the US. The US-based countries are continuously coming up with new-fangled SUS for effectively serving end-users at the global and local level. Europe is second seeded on the similar grounds. The Asia-Pacific is expected to grow at the fastest rate between 2020 and 2030 with importance of hygiene being preached all across. The countries like India are emphasizing on use of disposables to avert cross-contamination, especially after the outbreak of Covid-19 in the year 2020.

Some of the key market participants include Merck Milipore, Sartorius Stedim Biotech S.A., GE Healthcare, Danaher Corporation, and Thermo Fisher Scientific. The bioprocessing equipment developed by players include Sartorius Stedim’s FlexAct series, GE Healthcare’s FlexFactory or Ready to process series, Merck’s Mobius series, and Pall Life Sciences’ Allegro series. Also, there are suppliers like PendoTECH that are involved in hhaving a notable volume of its monitors and sensors sold to the key market participants for GMP production, toxicology, and pilot studies, along with clinical batches.

Additionally, Boehringer Ingelheim, in Jan 2019, did expand its commercial biologics-related manufacturing site all over China[1]. This expansion did cover incorporating bioreactor with the essential infrastructure and utility for supporting GMP operations of 2x 2.000L single-use bioreactor manufacturing lines.